Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the SWISS OPTICOV Study

NCT07406217 is registered in ClinicalTrials.gov with Calmy Alexandra as lead sponsor.

NCT NCT07406217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07406217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the SWISS OPTICOV Study
Lead sponsor
Calmy Alexandra
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2023
Completion date
June 30, 2026
Enrollment
256 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, immunodeficiency